The comments in there is exactly why the SP has levelled off. There is still very significant risk with this. If PAA want to further drive SP increase they would pay to do some further comms/messaging around why they believe the efficacy indications are significant, regardless of it only being 12 patients.
Not saying they have to, but it is the obvious fear that many hold. Some effort to try explain it may help, along with updates to the 12 patients ALSFRS as the OLE finalises.
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst, page-1022
-
- There are more pages in this discussion • 403 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
-0.005(2.38%) |
Mkt cap ! $91.22M | |||
| Open | High | Low | Value | Volume |
| 21.5¢ | 21.5¢ | 20.5¢ | $174.5K | 841.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 458470 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 144453 | 3 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| PAA (ASX) Chart |